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Alternative accessBackground: The axillary artery is an alternative route for patients with comorbidities and unfavorable femoral
arteries who need transcatheter aortic valve replacement (TAVR). Simplified trans-axillary transcatheter aortic
valve replacement (TAx-TAVR) implies a completely percutaneous approach under local anesthesia and
arteriotomy closure with vascular closure techniques. Herein, we report on early experience with simplified
TAx-TAVR under local anesthesia.
Methods:Weenrolled all consecutive patientswhounderwent simplified TAx-TAVR in our center.Main studypa-
rameter was the incidence of axillary access relatedmajor vascular complications within 30 days. Secondary pa-
rameters included a composite early safety endpoint, axillary access-site related vascular/bleeding complications
and short-term mortality. Post TAVR axillary stent patency was evaluated during follow-up by CT-analysis.
Results: Between July 2018 and April 2020, Tax-TAVR was attempted in 35 patients with a mean age of 79 years.
Local anesthesia and conscious sedation were used in 91.4% (n = 32) and 8.6% (n = 3) respectively. A covered
stent was needed for complete axillary hemostasis in 44.1% (n = 15). Device success was achieved in 91.2%
(n = 31/34). The 30-day axillary artery major vascular and ≥major bleeding complication rates were 14%
(n = 5) and 11% (n = 4). The early safety endpoint was reached in 22.9% (n = 8). Mortality rates at 30 days
and six months were 2.9% and 11.6%. Computed tomography (CT) confirmed axillary stent patency during
follow-up in 82% (n = 9/11).
Conclusions: In patients with high/prohibitive surgical risk and unsuitable femoral access, simplified TAx-TAVR
under local anesthesia offers a valuable alternative for transfemoral TAVR but requires advanced access siteman-
agement techniques including covered stents. Our data suggest an unmet clinical need for dedicated TAx closure
devices.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Transfemoral transcatheter aortic valve replacement (TAVR) is now
a valid alternative to surgical aortic valve replacement for symptomatic
severe aortic stenosis (AS) in elderly patients [1–4]. With unsuitable
femoral arteries, thoracic (apex and direct aorta) and upper body arte-
rial (carotid and axillary) routes are possible butmay come at increased
procedural risk and less favorable outcome [5–9]. TAVR registries in thenal Cardiology, Thoraxcenter,
D Rotterdam, the Netherlands.
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in approximately 15% of TAVR patients [7].
Alternative access typically requires surgical involvement and gen-
eral anesthesia. General anesthesia prolongs procedure time and in-
hospital stay [10]. Previous reports described the feasibility of a
completely percutaneous trans-axillary approach [11,12]. We further
simplified trans-axillary TAVR (TAx-TAVR) using (in principle) only
local anesthesia, ultrasound guided axillary artery access and
arteriotomy closure with vascular closure devices and covered stents
in case of incomplete closure [13].
Herein, we report on our early experiencewith simplified TAx-TAVR
in patients at high or prohibitive operative risk and no suitable femoraler the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tients in whom covered stents were required for closure device failure.
2. Methods
We enrolled all patients with an attempted TAx-TAVR in the Eras-
mus University Medical Center (EMC).
Eligibility for TAx-TAVR was by heart team consensus involving im-
aging specialists, interventional cardiologists, cardiac surgeons and ger-
iatricians. All patientswere deemed at high or prohibitive operative risk.
CT evaluation ruled out safe femoral artery accessibility (for large-bore
sheaths) and confirmed axillary artery suitability to accommodate
large bore access for TAVR. This included an axillary diameter of >5mm.
A dedicated database captured relevant patient demographics, co-
morbidities, clinical status, ECG, echocardiography, CT and procedure
data. Adverse events were classified according to the Valve Academic
Research Consortium II consensus document (VARC-II) [14]. All patients
were followed up in the outpatient clinic at 30 days post-TAVR. Patients
in whom a covered stent was required to achieve complete hemostasis
after closure device failure underwent follow up CT evaluation of the
stented artery. All patients provided written informed consent for the
TAVR procedure and subsequent data analysis for research purposes.
The study complied to the principles of the Declaration of Helsinki and
did not fall under the scope of the Medical Research Involving Human
Subjects Act per EMC Institutional Review Board.
2.1. Simplified transaxillary aortic valve recplacement under local
anesthesia
Our completely percutaneous trans-axillary aortic valve replace-
ment technique under local anesthesia has been described elsewhere
[13]. In brief, ultrasound guided lidocaine administration and large
bore access to the axillary artery was obtained in the deltopectoral
groove, to avoid entry into the thoracic space (Fig. 1A-B). Left side access
was preferred unless the left internal thoracic artery had been used for
coronary bypass surgery or in case of unattractive left axillary/subcla-
vian artery appearance (tortuosity, atherosclerotic disease, calcium). A
7F Slender sheath (Terumo Corp., Somerset NJ) was inserted in theFig. 1. Aspects of axillary access and arteriotomy closure. (A) Ultrasound guided access of the ri
towards the axillary artery. (C) Overview of right axillary (lower red arrow) and radial (upper
artery. (E) Position of the operator during deployment of closure device. (F) Angiographic che
marker of the VCD does not make contact with the vessel wall. (G) Deployment of a 6 mm c
shows complete hemostasis. Adequate stent expansion was confirmed (red box). (For interpr
version of this article.)
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ipsilateral radial or ulnar artery to accommodate bail out stent delivery
when needed (Fig. 1C). Additional 6F access was obtained to a common
femoral artery or (in the later experience) contralateral radial artery to
advance a pigtail catheter for contrast injections (Fig. 2).
The TAVR procedure evolved with contemporary self-expanding
supra-annularly functioning transcatheter heart valves (14F Evolut R
or 16F Evolut Pro or 16F Evolut XL, Medtronic Inc. Minneapolis, MN).
Percutaneous large bore arteriotomy closure was attemptedwith either
a plug-based MANTA (Teleflex, Wanye, PA) or double suture-based
ProGlide (Abbott Laboratories, Chicago, IL) technique (Fig. 1D-E). A 6F
diagnostic catheter was advanced through the ipsilateral radial/ulnar
artery and parked distal to the arteriotomy site for selective angiogra-
phy after sheath removal and arteriotomy closure to confirm hemosta-
sis and/or advance an 0.035″ wire for ballooning or (covered) stenting
(Figs. 1F-H, 2).
2.2. Study parameters
The main study endpoint was the incidence of axillary access major
vascular complications within 30 days. Secondary endpoints included a
composite of mortality, stroke, acute kidney injury stage II-III, coronary
obstruction and valve related dysfunction requiring a repeat procedure
at 30 days (VARC-II early safety endpoint), all major andminor vascular
complications and VARC-II specified bleeding complications related to
the axillary access and need for new permanent pacemaker implanta-
tion at 30 days [14]. Additionally, incidence of an in-hospital delirium
as evaluated by a geriatrician was recorded.
Contemporary vascular closure devices were originally designed for
femoral use but were applied for axillary arteriotomy closure in this
study. Because of its extra-thoracic location, the axillary artery could
bemanually compressed in case of closure device failure and additional
bail out maneuvers could be applied to achieve hemostasis. Adjunctive
covered stenting was considered part of the procedure and was there-
fore not deemed a vascular complication.We opted for balloon expand-
able Advanta V12 covered stents (Maquet, Rastatt, Germany) that are 7F
compatible and could be delivered through the 7F slender sheath that
was inserted in the radial/ulnar artery downstream from the large
bore axillary access. Successful arteriotomy closure was defined byght axillary artery. (B) Echocardiographic view of the advancing needle (within red circle)
red arrow) access. (D) Deployment of MANTA vascular closure device at the right axillary
ck after closure with evident blush at the arteriotomy site (red arrow). The radio-opaque
overed stent in the right axillary artery. (H) Angiographic control after stent placement
etation of the references to colour in this figure legend, the reader is referred to the web
Fig. 2. Access sites in simplified trans-axillary TAVR - a schematic overview. The left axillary artery is the primary access site. Should the procedure be performed with the right axillary
artery as the primary access site, the function of the right and left radial artery accesses are interchanged. (*) Rapid pacing during implantation is done over the left ventricular guidewire.
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stent if needed.Table 1
Baseline characteristics.
Baseline characteristics n = 35
Age - years 78.7 ± 6.3
Male 20 (57.1)
Hypertension 26 (74.3)
Diabetes mellitus 15 (42.9)
Stroke/TIA 6 (17.1)2.3. Follow-up of covered stent patency
All patients who received a covered stent in the axillary artery for
hemostasis underwent CT angiography during follow up to assess
stent patency, deformation or fracture. Patency was defined as the ab-
sence of >50% narrowing of the stent lumen relative to the distal refer-
ence vessel diameter (i.e. no stenosis), deformationwas defined as stent
bending leading to a significant stenosis [15]. Stent fracture was scored
according to standardized fracture grading [16]. Patients were clinically
assessed for signs and symptoms of ipsilateral distal ischemia during in-
hospital stay and at the 30-days follow up visit.Peripheral vascular disease 35 (100.0)
COPD 14 (40.0)
Chronic kidney disease (GFR <35 ml/min) 7 (20.0)
Previous myocardial infarction 8 (22.9)
Previous percutaneous coronary intervention 14 (40.0)
Previous coronary-artery bypass grafting 8 (22.9)
Previous TAVR 1 (2.9)
Previous aortic valve surgery 1 (2.9)
Previous non-aortic valve surgery 2 (5.7)
Atrial fibrillation 14 (40.0)






STS-PROM score 4.3 ± 1.82.4. Statistics
Continuous variables were presented as mean with standard devia-
tion (SD) if normally distributed. Median with interquartile range [IQR]
was provided if not normally distributed. Pre and post TAVR invasive
measurements were analyzed using paired t-tests or Wilcoxon signed-
rank test depending on normality. Nominal data are presented as fre-
quencies and compared using either Pearson's Chi-square or Fishers
exact test for unpaired data if applicable. A Kaplan-Meier estimate was
used to estimate 6-month survival probability. A two-sided P value of
<0.05 was considered to indicate statistical significance. All statistical
analyses were performed with SPSS 25.0 (IBM, Armonk, NY).HAS-BLED scoreα 5.8 [4.1–5.8]
Baseline anticoagulation and anti-platelet therapy
Vitamin K antagonist or NOAC 14 (40.0)
Aspirin 17 (48.6)
Clopidogrel or Ticagrelor 13 (37.1)
Baseline echocardiogram
LVEF (%) 52.2 ± 10.6
LVEF ≤25% 2 (5.7)
Aortic stenosis - severe 34 (97.1)
Aortic regurgitation ≥moderate 5 (14.3)
Mitral regurgitation ≥moderate 5 (14.3)
Tricuspid regurgitation ≥moderate 4 (11.4)3. Results
A total of 35 patients underwent an attempted TAx-TAVR. The indi-
cationwas a severe symptomatic native aortic stenosis in 34 (97.1%) pa-
tients and a failing surgical bioprosthesis with severe regurgitation in 1
patient. All patients were treated between July 2018 and April 2020 and
our Tax-TAVR cohort represented 7.4% (n = 35/473) of the total TAVR
cohort in that time window. Tax-TAVR was the only non-transfemoral
approach after transapical access was no longer applied since
early 2018.3
3.1. Baseline and procedural characteristics
Baseline demographics are displayed in Table 1. Mean age was
78.7 years (SD±6.3) and all patientswere suffering fromperipheral ar-
terial disease that precluded transfemoral TAVR. Mean Society of
Table 3





Mortality 1 (2.9) 1 (2.9)
- Cardiovascular cause 1 (2.9) 1 (2.9)
Acute myocardial infarction 0 0
Stroke 2 (5.7) 2 (5.7)
TIA 1 (2.9) 1 (2.9)
New permanent pacemaker 5 (14.3) 5 (14.3)
Acute kidney Injury
- Stage I 2 (5.7) –
- Stage II 1 (2.9)
- Stage III 0
Non-access site*
- Life threatening bleeding 1 (2.9) 1 (2.9)
- Major vascular complication 1 (2.9) 1 (2.9)
Delirium 3 (8.6) 3 (8.6)
Admission time (days) 5 [3–8] –
Access site related complications
Access site related vascular complicationβ
- Major 4 (11.4) 5 (14.3)
- Minor 0 0
Reintervention at access site 1 (2.9) 2 (5.7)
Access site related bleeding
- Life threatening 2 (5.7) 2 (5.7)
- Major 2 (5.7) 2 (5.7)
- Minor 3 (8.6) 3 (8.6)
Freedom from access site related major vascular
complication or ≥major bleeding
31 (88.6) 30 (85.7)
Brachial plexus impairment access site arm 2 (5.7) 2 (5.7)
Early safety endpoint and functional class at 30 days
Composite early safety endpoint – VARC II – 8 (22.9)
Any NYHA class improvement – 24
(80.0+)
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4.3% (SD± 1.8). All patients were deemed at high or prohibitive opera-
tive risk by heart team consensus. Reasons were: advanced frailty (n=
17), hostile chest and previous thoracic surgery (n=8), advanced lung
disease (n=4), activemalignancy (n=3), poor LVFwith advanced age
(n = 2) and patient refusal (n = 1).
Procedural characteristics are tabulated in Table 2. Thirty-two pa-
tients (91.4%) received local anesthesia only and 3 patients (8.6%) con-
scious sedation. Access was obtained via the left axillary artery in 25
(71.4%) and via the right axillary artery in 10 (28.6%) patients. Femoral
arteries were left untouched in 12 (34.3%) patients (i.e. pigtail or safety
wire via radial arteries). One patient suffered a stroke while advancing
the delivery catheter and the procedure was abortedwith no transcath-
eter valve implant. The 14F Evolut R was the preferred transcatheter
heart valve (THV) because of its lowest profile and was used in 91.2%
of patients. Two patients needed >1 THV implant. Device success was
achieved in 31 (91.2%) patients. One procedural death resulted from
aortic root rupture after TAVR and postdilatation.
Axillary arteriotomy closure was attempted with a VCD in 34 pa-
tients. A MANTA VCD was used in 31 (91.2%) patients and double
ProGlides in 3 (8.8%). VCD failure occurred in 15 (44.1%) patients
(MANTA n = 14/31, double ProGlide n = 1/3) and required covered
stent implantation to achieve complete hemostasis. Percutaneous
arteriotomy closure was accomplished in 33 (97.1%) patients. Median
procedure time was 67 min (IQR 41–134) and median amount of con-
trast used was 80 ml (IQR 61–100). Invasive hemodynamic measure-
ments over the aortic valve are reported in Supplementary Table 1. No
significant residual gradients over the aortic valvewere observed. Mod-
erate paravalvular leak occurred in one patient (3.0%).
In-hospital and 30 day complications are reported in Table 3. Overall
mortality was restricted to the patient who died per procedurally.
Stroke occurred in 2 (5.7%) patients, including the patient in whom
the TAVRwas aborted, while one (2.9%) patient experienced a transient
ischemic attack (TIA). Acute kidney injury (AKI) stage II occurred in 1Table 2
Procedural characteristics.






Valve in valve 2 (5.7)






More than one valve placedα 1 (2.9)
Predilatationα 4 (11.8)
Postdilatationα 13 (38.2)
VARC-II device success*α 31 (91.2)




Heparin used (IU) 5000 [5000–6000]
Protamine used (no.) 9 (25.7)
Contrast used (ml) 80 [61–100]
Procedure time (min) 67 [41–134]
Access-site related characteristics
Completely non-femoral 12 (34.3)
Axillary access side
- Left 25 (71.4)
- Right 10 (28.6)
Closure deviceβ
- MANTA 31 (91.2)
- Double ProGlide 3 (8.8)
VCD failure – VARC IIβ 15 (44.1)
Covered stent usedβ 15 (44.1)
Successful arteriotomy closure§β 33 (97.1)
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patient (2.9%). Five patients (14.3%) required a permanent pacemaker
due to a total AV-block.
3.2. Vascular and bleeding complications
The main endpoint of axillary access major vascular complications
occurred in 5 (14.3%) patients. In one patient a malapposed covered
stent resulted in continued bleeding at the arteriotomy site, which
was resolved by postdilatation. One patient experienced a major bleed-
ing around the access site requiring multiple transfusions. One patient
(in whom the TAVR was aborted as described above) suffered an axil-
lary artery dissection that generated a stroke and life-threatening bleed-
ing with an active blush on CT which was treated with manual
compression and multiple transfusions. In another patient, significant
procedural blood loss caused a large hematoma and required intermit-
tent vasopressor support (qualified as a life-threatening bleeding).
Lastly, one patient experienced amajor vascular complication after hos-
pital discharge with bilateral upper extremity paresthesia and pain. The
right axillary covered stent appeared underexpanded and the left radial
artery (that had received a 6F radial sheath) showed a total occlusion.
The stent was postdilated and a PTAwas performed in the left radial ar-
tery. The total number of access site reinterventions by day 30 was 2
(5.7%) (both featured a postdilatation). Major and life-threatening
access-site related bleeding complications occurred in 2 (5.7%) and 2
(5.7%) patients respectively. Three patients (8.6%) experienced minor
access-site related bleedings.
Median hospital stay was 5 days [IQR 3–8] and included admission
time in referring hospitals. Delirium, diagnosed by a geriatrician, oc-
curred in 3 (8.6%) patients. At 30 days, 30 (85.7%) patients were free
of access-site related major vascular or ≥major bleeding complications.
The VARC-II defined early safety endpoint at 30 days was reached in
8 (22.9%) patients (Table 3 and Supplementary Table 2). The incidence
of the primary endpoint, major bleeding and the early safety endpoint
J.F. Ooms, M.P. Van Wiechen, T.W. Hokken et al. Cardiovascular Revascularization Medicine xxx (xxxx) xxxremained stable throughout the experience (no initial learning curve ef-
fect) (Supplementary Table 3). NYHA functional class at 30 days was
improved by ≥1 grade in 80% of patients. Median follow-up duration
was 56 days [IQR 39–198] with a 30 day and 6 month mortality of 1
(2.9%) and 3 (8.6%) respectivelywith a Kaplan-Meier estimated survival
at 6 months of 88.4%.
Twopatients developed post-procedural brachial plexus neuropathy
of the access-site arm. One patient (who had received a covered stent)
experienced subtle limitations of fine motor skills of the ipsilateral
hand that persisted at 1-year clinical follow up while the other patient
(who had an otherwise uneventful course) reported transient sensory
impairment of the ipsilateral fingers.
Of the 15 patients who received a covered stent 11 (73%) had a
follow-up CT of the axillary artery at a mean follow-up of 205 days
(Table 4). Two patients (18%) showed stent deformation and significant
stenosis of which details are described in Fig. 3. No vessel occlusions or
strut fractures were observed. CT-confirmed stent patency was 82%
(n = 9/11).
4. Discussion
This case series describes our initial experience with a completely
percutaneous simplified TAx-TAVR technique. Main observations are:
1) simplified TAx-TAVR was feasible and relatively safe. 2) Axillary ar-
tery major vascular and ≥major bleeding complication rates were 14%
and 11% respectively. 3) Contemporary vascular closure device technol-
ogy (originally designed for femoral arterial access closure) had impor-
tant flaws and therefore covered stents should be considered an
essential part of simplified TAx-TAVR. 4) Bail-out covered stent place-
ment to secure complete hemostasis requires meticulous implantation
and may include low-threshold postdilatation to achieve complete ex-
pansion, apposition and secure stent patency.
Percutaneous axillary access was applied in 7.2% of the overall TAVR
population, which is consistent with recent European and American
registries and underscores the importance of alternative non-
transfemoral routes [7,17,18]. Alterative access patients typically have
extensive peripheral arterial disease and other comorbidities. Still, we
demonstrated device implantation success in 91.2% with the simplified
TAx approach under local anesthesia which mimics the results of other
TAx-TAVR and alternative access routes that predominantly required
general anesthesia and/or surgical techniques. Surgical cut-down as
typically applied in a transapical, direct aortic, transcarotid or subclavian
approach increases patient morbidity [19–21]. General anesthesia and
mechanical ventilation may also imply need for post procedural ICU
care and potential subsequent complications [22]. TAx-TAVR in awake
patients may expedite procedure and recovery time, preclude ICU
care, reduce the risk for infections and delirium and offers the ability
for per procedural monitoring for neurological events. Indeed, 1 case
in our series was aborted as the patient was losing consciousness
while advancing the delivery catheter through the subclavian artery.
The avoidance of general anesthesia may have also contributed to the
relatively low post-operative delirium rate (8%) which compares to ap-
proximately 21% in other series of non-femoral TAVR [23], short proce-
dure time (median of 67 min) and decreased in-hospital stay (medianTable 4
Post procedural CT assessment of axillary stent.
Post procedural CT assessment of axillary stent No. (%)
(n = 11)
Days to follow-up CT-scan 205 [2–440]
Stent stenosis
- Due to deformation 2 (18.2)
- Due to thrombus 0
Stent occlusion 0
Strut fracture (any) 0
Stent patency 9 (81.8)
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5 days vs. mean 8 days in other TAx-TAVR series) [11]. The TAx ap-
proach further grants the ability to directly monitor the access site and
may be less prone to covert bleedings as opposed to the completely per-
cutaneous transcaval strategy that may be associated with occult retro-
peritoneal bleedings [20]. We believe access to the subclavian artery
comes with a risk of pneumothorax and occult intrathoracic bleedings
and is therefore less suitable for a completely percutaneous approach.
Our series demonstrated the limitations of current generation vascu-
lar closure devices with a need for bail out covered stents in almost half
of the attempted cases. ProGlide and MANTA VCD were originally de-
signed for the common femoral artery, which is notably different from
the axillary artery (i.e. thinner wall, surrounded by more rigid tissue).
Further modification of a plug-based closure technique by deploying
the toggle under ultrasound guidance was recently suggested, however
it remains questionable whether this will improve VCD success in gen-
eral and with the axillary approach in particular [24]. Until dedicated
axillary VCDs are available, covered stents remain an indispensable
part of the toolbox for completely percutaneous TAx-TAVR. The 97.1%
arteriotomy closure success rate should be weighed against the 14%
major vascular complication rate but may be acceptable in patients
who appeared at high/prohibitive operative risk with no transfemoral
access. Additionally, as this is an initial experience with novel tech-
niques, these rates are expected to decrease as numbers increase.
The VARC-II defined early safety endpoint was reached in 8 (22.9%)
patients and is mainly driven by the number of major vascular compli-
cations. An explanation for these numbers can be found in the substan-
tial baseline morbidity of our cohort. All patients suffered from
peripheral vascular disease, hypertension was common and comorbid-
ities associated with bleeding risk were extensive (i.e. elevated
HASBLED-score at baseline). The reported numbers are in line with
the previously reported high-risk cohorts and lead to similar rates of
vascular complications [1,25].
Studies on completely percutaneous TAx-TAVR are scarce. The Ham-
burg experience on 100 consecutive patients reported a remarkably low
complication rate [11]. The Hamburg technique included general anes-
thesia (in 72% of cases), the creation of an arterial femoral-radial rail,
and suture-based closure with balloon occlusion. Procedure time was
85 min and mean amount of contrast used was 167 ml (vs. medians of
67 min and 80 ml in our cohort). Closure device success appeared
higher with an 11% covered stent use vs. 44% in our series. We intro-
duced the plug basedMANTA VCD for its relatively rapid time to hemo-
stasis, single device use and marking of the arteriotomy site on
angiography. Arguably, this technology was not developed for axillary
access, precludes the use of additional closure devices in case of failure
and cannot be applied using the balloon occlusion technique because
adequate blood pressure is required for optimal deployment of the in-
travascular device component. Mortality at 30 days follow-up was de-
creased compared to the incidence reported by the Hamburg group
(2.9% vs. 6%).
Persistent brachial plexus injury with the axillary approach at the
deltopectoral groovewas rare in our series and seemed nomajor clinical
issue as previously suggested [26]. Of note, the two reported cases in
this series both followed a bleeding event with prolonged manual
compression.
To our knowledge, this is the first study to report on CT-assessed ax-
illary stent patency post TAx-TAVR. CT analysis of patientswho received
a covered stent confirmed two cases (18% of scanned patients) of signif-
icant stent deformation and stenosis with only 1 being symptomatic.
These scans provide important information on the mechanism of stent
deformation in post TAx-TAVR patients. In both patients, stent deforma-
tion and stenosis was evidently located next to an osseous structure
(rib, humeral head) (Fig. 3B-C) and in both patients post-procedural
and post-stent deployment manual compression was required. Con-
ceivably, the relatively superficial location of the axillary artery close
to bone structures (humeral head and 1st rib) allows complete hemo-
static control through manual compression but may come at the price
Fig. 3. CT-assessed axillary stent patencypost TAx-TAVR. (A) Patient 1, stent patency: frontal viewof the aortic arch andbranches (calcium settings)with a clear view of the stent in the left
axillary artery (green circle). Stent structure appears intactwithout any deformations or stenosis. The stretched vessel image of the stent does not show any signs of intra-stent obstruction
(green cadre). (B) Patient 2, no stent patency: frontal view of the brachiocephalic trunk and right axillary artery (contrast/bone settings). The distal stent edge has been compressed
(direction of red arrow) against the glenohumeral joint (dotted red line). Significant distal lumen loss is shown on the stretched vessel (red cadre) with contrast present in the distal
part of the vessel. The patient was symptomatic and treated with postdilataion. (C) Patient 3, no stent patency: frontolateral view (simulated C-arm angles: RAO40, CAU22) of the
aortic arch and branches with the stent in the axillary artery highlighted (red circle). The proximal part of the stent is deformed. Significant proximal lumen loss is shown on the
stretched vessel (red cadre). Bending of the stent over the distal part of the first rib (red asterisk) might have caused the stent to be pinched. Contrast is present in the distal part of
the vessel and the patient was asymptomatic. Images were obtained using 3Mensio software (Pie Medical, Maastricht, The Netherlands). (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
J.F. Ooms, M.P. Van Wiechen, T.W. Hokken et al. Cardiovascular Revascularization Medicine xxx (xxxx) xxxof brachial plexus injury and stent deformation. This underscores the
importance of appropriate covered stent apposition and expansion in-
cluding postdilatation if needed to obtain immediate complete hemo-
stasis and avoid the need for additional manual compression.6
5. Limitations
This single center study has several limitations. First, most patients
qualify for transfemoral TAVR. Therefore the sample size is relatively
J.F. Ooms, M.P. Van Wiechen, T.W. Hokken et al. Cardiovascular Revascularization Medicine xxx (xxxx) xxxlimited. Second, multiple patients did not present at the outpatient
clinic at one year follow-up, resulting in an inability to report on
VARC-II defined adverse events beyond 30 days. Third, not all patients
with a covered stent had a follow-up CT available which might have
led to underreporting of asymptomatic stent deformation. Fourth,
timing of follow up CT varied, precluding a comparison of axillary
stent performance over time.
6. Conclusion
In patientswith high or prohibitive surgical risk and no suitable fem-
oral access site, simplified TAx-TAVR under local anesthesia offers a
valuable alternative for transfemoral TAVR but requires advanced ac-
cess site management techniques including covered stents. Our data
suggest an unmet clinical need for dedicated TAx closure devices.
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